First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, , Cologne, Germany.
Ann Hematol. 2022 Feb;101(2):389-395. doi: 10.1007/s00277-021-04698-3. Epub 2021 Oct 20.
The prognosis of allogeneic stem cell transplant recipients admitted to the intensive care unit (ICU) has improved over the last decades. However, data focusing on patients treated in the ICU during the peri-transplant period are scarce. We therefore conducted an analysis comprising 70 patients who had allogeneic stem cell transplantation at the University Hospital Cologne between 2014 and 2020 and were admitted to the ICU between the initiation of conditioning therapy and day 30 after transplantation. The median age was 59 years (range: 18 - 72 years). 50% of patients were female. Sepsis was the most common cause for ICU admission (49%). Mechanical ventilation (MV) was required in 56% of patients, 27% had renal replacement therapy (RRT), and 64% needed vasopressors. The ICU, hospital, 90-day, and 1-year survival rates were 48.6%, 38.6%, 35.7%, and 16.2%, respectively. MV and/or RRT during the ICU stay were associated with an impaired survival (p < 0.0001). The same was true for the use of vasopressors (p < 0.0001). In contrast, baseline characteristics did not impact the outcome. Cardiopulmonary resuscitation (CPR) was performed in 17% of patients. None of the patients undergoing CPR was alive at 1 year. Among patients who died after discharge from the ICU (n = 23), sepsis and other infectious complications represented the major causes of death (48%). Taken together, the present analysis indicates unfavorable outcomes for allogeneic stem cell transplant recipients admitted to the ICU during the peri-transplant period. The data may help to make informed decisions with patients and their families.
在过去几十年中,接受同种异体干细胞移植的重症监护病房(ICU)患者的预后有所改善。然而,针对移植期间 ICU 治疗患者的数据却很少。因此,我们对 2014 年至 2020 年期间在科隆大学医院接受同种异体干细胞移植且在移植前诱导治疗开始至移植后 30 天期间入住 ICU 的 70 例患者进行了分析。患者的中位年龄为 59 岁(范围:18-72 岁)。50%的患者为女性。败血症是 ICU 入住的最常见原因(49%)。56%的患者需要机械通气(MV),27%的患者需要肾脏替代治疗(RRT),64%的患者需要升压药。ICU、医院、90 天和 1 年的生存率分别为 48.6%、38.6%、35.7%和 16.2%。MV 和/或 ICU 期间的 RRT 与生存率降低相关(p<0.0001)。升压药的使用也如此(p<0.0001)。相比之下,基线特征并不影响结果。17%的患者进行了心肺复苏(CPR)。在接受 CPR 的患者中,没有一个在 1 年后存活。在从 ICU 出院后死亡的患者(n=23)中,败血症和其他感染性并发症是主要死亡原因(48%)。综上所述,本分析表明移植期间入住 ICU 的同种异体干细胞移植患者预后不良。这些数据可能有助于与患者及其家属做出明智的决策。